ECIAOTCSurgical & Medical Instruments & ApparatusUS GAAP · USD

Encision Inc

Encision Inc. designs and sells Active Electrode Monitoring (AEM) surgical instruments and related products that are intended to reduce the risk of stray electrosurgical energy during minimally invasive surgery. The company also offers disposable and multi-use laparoscopic scissors, monitors, and related accessories, and it supports adoption through direct sales, independent distributors, and hospital education efforts.

Liikevaihto6,6milj. USD
−0,5 %v/v
Liikevoitto (EBIT)−0,2milj. USD
+73,2 %v/v
EBIT-marginaali−2,6%
+7,1 %-yks.v/v
Nettotulos−0,2milj. USD
+68,2 %v/v
Vapaa kassavirta−0,1milj. USD
−182,6 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−202468milj. USD2020: 7,7 milj. USD2020: EBIT −0,16 milj. USD20202021: 7,5 milj. USD2021: EBIT −0,06 milj. USD20212022: 7,7 milj. USD2022: EBIT −0,59 milj. USD20222023: 7,3 milj. USD2023: EBIT −0,30 milj. USD20232024: 6,6 milj. USD2024: EBIT −0,64 milj. USD20242025: 6,6 milj. USD2025: EBIT −0,17 milj. USD20256,6−0,17
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
AEM surgical instruments55 %

Monopolar surgical instruments designed to monitor and reduce stray electrosurgical energy risk.

Scissors and cutting instruments30 %

Disposable and multi-use laparoscopic scissors sold for hot and cold dissection.

Monitors and accessories10 %

Monitoring devices and related accessories that support the AEM product ecosystem.

Services and development work5 %

Proof-of-concept and technical services tied to robotic and minimally invasive surgery.

Tuotteet

Raportoitu · osuus liikevaihdosta
94,8%FY2025100 %
  • Products94,8 %
  • Services5,2 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Encision sells primarily to hospitals, surgeons, and healthcare systems that perform minimally invasive and laparoscopic procedures. Adoption is driven by patient-safety concerns, clinical education, and hospital purchasing channels such as GPOs, integrated delivery networks, and the U.S. Veterans Affairs system.

Hospitals and surgical centers

Buy AEM instruments, scissors, and monitors to reduce electrosurgical injury risk and improve OR workflow.

Group Purchasing Organizations (GPOs)

Contract for broader hospital access and help standardize adoption across member facilities.

Integrated delivery networks and hospital systems

Purchase through system-wide sourcing agreements to standardize surgical products across facilities.

Veterans Affairs medical centers

Use the company’s patient-safety technology in a large U.S. healthcare network.

International distributors

Market products in Australia, New Zealand, and selected European markets where CE marking enables sales.

Strategia

Encision’s strategy is to broaden adoption of AEM technology by educating hospitals and surgeons about electrosurgical injury risk and by expanding its sales network. It is also trying to deepen access through GPOs, hospital systems, and distributors while using product innovation such as the 2X Scissors to widen use cases and improve value perception.

Broaden U.S. hospital adoptionLyhyt aikaväli

The company needs more operating-room penetration to drive recurring product sales.

Increase awareness of AEM patient-safety benefitsLyhyt aikaväli

Demand depends on convincing clinicians and hospitals that monitored electrosurgery reduces risk.

Extend product usage with 2X ScissorsKeskipitkä aikaväli

A lower-cost multi-use device can open new use segments and standardize customers on the portfolio.

Build international distributionKeskipitkä aikaväli

CE marking and overseas distributors create incremental market opportunities beyond the U.S.

Maantiede

2025

The company is headquartered in the United States and most of its business is focused on U.S. hospitals and surgical networks. International sales are still small, but it has distributors in Australia and New Zealand and CE marking allows access to Europe as distribution channels develop.

Australia87 %
New Zealand13 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

Encision’s business depends on convincing hospitals and surgeons to adopt a niche safety technology, so market acceptance and long sales cycles are central risks. It also faces supply-chain concentration, intense competition from larger electrosurgical manufacturers, regulatory oversight, cybersecurity exposure, and quarterly volatility typical of a small medical-device company.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Limited market acceptance of AEM technology1Supply chain concentration2Regulatory compliance and approval risk3Competitive pressure from larger medical-device companies4
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Limited market acceptance of AEM technologyVaikutus: KorkeaTodennäköisyys: Korkea

    Demand depends on educating hospitals about electrosurgical hazards and proving clinical value.

    Kohdistuu: Hospital operating rooms and laparoscopic surgery channels

  2. Supply chain concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company relies on single-source suppliers and subcontractors for key components and assemblies.

    Kohdistuu: Manufacturing lead times and product availability

  3. Regulatory compliance and approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    FDA and other agencies can inspect, restrict, or delay manufacturing and product approvals.

    KohdistuuManufacturing facilitiesProduct clearancesQuality systems
  4. Competitive pressure from larger medical-device companiesVaikutus: KeskitasoTodennäköisyys: Korkea

    Rivals have greater financial, technical, and marketing resources and entrenched products.

    Kohdistuu: Electrosurgical instruments and alternative surgical technologies

  5. Cybersecurity and data breach riskVaikutus: Keskitaso

    IT systems handle sensitive customer and employee information and could be disrupted or compromised.

    KohdistuuOperationsReputationPotential legal liabilities

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition timing

Product sales likely recognize when control transfers, so shipment timing can move revenue between quarters.

Vaikutus: Affects quarterly comparability and reported growth rates

Inventory valuation and obsolescence

A focused product portfolio and long lead times increase the need to assess excess or obsolete stock.

Vaikutus: Can affect gross margin and operating results

Impairment of long-lived assets or intangibles

If adoption remains weak, asset values tied to product development or operations may need review.

Vaikutus: Could create non-cash charges in weak periods

Quarterly volatility and seasonality

Small order sizes and hospital purchasing cycles can cause uneven revenue and expense recognition.

Vaikutus: Makes trend analysis and guidance less predictable

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 24.9.2026

Encision Inc (OTC) – Surgical & Medical Instruments & Apparat | Analyysi – Clarifo